Loading…
Loading…
IFRX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IFRX and 80,000+ other tickers.
See exactly how IFRX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IFRX and 80,000+ other tickers.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully…
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows:
Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&I) indications Virtual Capital Markets Day planned for October 8, 2026 in the morning ET Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, including net proceeds from the underwritten public offering completed in May, expected to fund ongoing operations and clinical development through 2029 Jena, Germany, Aug. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced financial results for the three months ended June 30, 2026, and provided a business update.
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. No conference call is planned.
Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Institutional and Insider Ownership 20.4% of Kamada shares are
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessment given the recommendation of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to revoke the marketing authorization for Tavneos in the European Union, announced on June 26, 2026.